Your position:m.limatoxi.com >> EN >> EN >> Formulation >> Pfizer Receives Conditional Approval for Tislelizumab in the Treatment of Relapsed or Refractory Extranodal NK/T-cell Lymphoma (ENKTL) >> article
 
Pfizer Receives Conditional Approval for Tislelizumab in the Treatment of Relapsed or Refractory Extranodal NK/T-cell Lymphoma (ENKTL)
Editor:xuezhe     Clicks:0    Date:2023-11-3 15:37:28
Keyword: Extranodal
Healthoo Information:
Pfizer Receives Conditional Approval for Tislelizumab in the Treatment of Relapsed or Refractory Extranodal NK/T-cell Lymphoma (ENKTL)
 
 E-mail:xuezhe@healthoo.com
 Tel.:86-10-68032463
  Our services:
 China Im\Ex data service
 Service fees of Chinese Vision
 Our service items
Online information introduction
Monthly information
Relative Information
Address: Suite 13F,NO2 Building, FuXing International, TianHua North Street, Yizhuang, Daxing District, Beijing, P.R. China
Tel:+86-10-68032463
Baidu
map